SUVEN PHARMA

Annexure XI

Date: 1st March 2024

The General Manager,
Department of Corporate Services,
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 543064

Ref: **Application for obtaining approval under Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the scheme of amalgamation of Cohance Lifesciences Limited into and with Suven Pharmaceuticals Limited under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Scheme of Amalgamation").**

It is hereby certified that the draft scheme of amalgamation of Cohance Lifesciences Limited ("**Transferor Company**") into and with Suven Pharmaceuticals Limited ("**Transferee Company**") under Sections 230 to 232 of the Companies Act, 2013 and other applicable provisions ("**Scheme of Amalgamation**") does not, in any way violate, override or limit the provisions of securities laws or requirements of the Stock Exchange(s) and the same is in compliance with the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**") and the SEBI Circular, including the following:

Sr. No.	Reference	Particulars	Compliance
1.	Regulations 17 to 27 of the SEBI Listing Regulations	Corporate governance requirements	Yes, complied.
2.	Regulation 11 of the SEBI Listing Regulations	Compliance with securities laws	Yes, complied.
Requirements of SEBI Circular			
(a)	Para (I)(A)(2)	Submission of documents to Stock Exchanges	Yes, complied.
(b)	Para (I)(A)(3)	Conditions for schemes of arrangement involving unlisted entities	Yes, complied. Noted for compliance with respect to the preparation of the abridged prospectus.
(c)	Para (I)(A)(4)(a)	Submission of Valuation Report	Yes, complied.
(d)	Para (I)(A)(5)	Auditors certificate regarding compliance with Accounting Standards	Yes, complied.
(e)	Para (I)(A)~~(9)~~10	Provision of approval of public shareholders through e-voting	Noted for compliance.

For **Suven Pharmaceuticals Limited**

K. Hanumantha Rao
Company Secretary & Compliance Officer
Membership No. A11599

SUVEN PHARMACEUTICALS LIMITED * HYD *

For **Suven Pharmaceuticals Limited**

V. Prasada Raju
Managing Director
DIN: 07267366

Certified that the transactions/ accounting treatment provided in the draft Scheme of Amalgamation involving the Transferor Company (i.e., Cohance Lifesciences Limited) and the Transferee Company (i.e., Suven Pharmaceuticals Limited) are in compliance with all the Accounting Standards applicable to a listed entity.

For **Suven Pharmaceuticals Limited**

Himanshu Agarwal
Chief Financial Officer
M. No. A92452

For **Suven Pharmaceuticals Limited**

V. Prasada Raju
Managing Director
DIN: 07267366

Suven Pharmaceuticals Limited
Regd. Office: 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue 7,
Banjara Hills, Hyderabad - 500 034. Telangana, India. CIN : L24299TG2018PLC128171
Tel: 91 40 2354 9414, Fax : 91 40 2354 1152, Email: info@suvenpharm.com, Website : suvenpharm.com